Retinopathy Of Prematurity Clinical Trials Market Review H2 2014

Retinopathy of prematurity (ROP) is abnormal blood vessel development in the retina of the eye. It occurs in infants that are born too early. The blood vessels of the retina begin to develop about 3 months into pregnancy. They complete development at the time of normal birth. The eyes may not develop properly if a baby is born very early. The vessels may stop growing or grow abnormally from the retina into the back of the eye. The vessels are fragile. They can leak and cause bleeding in the eye.

Companies Participating in Retinopathy Of Prematurity Therapeutics Clinical Trials:-

·         Shire Plc

·         Mednax, Inc.

·         Insmed Incorporated

·         Gene Signal International SA

·         EyeGene, Inc.

“Retinopathy Of Prematurity Global Clinical Trials Review, H2, 2014″ provides data on the Retinopathy Of Prematurity clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Retinopathy Of Prematurity. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Retinopathy Of Prematurity. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

To get Discount on this report, visit: .

This is a premium report priced at US$2500 for a single user PDF.


Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in eachClinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor typeListings of discontinued trials (suspended, withdrawn and terminated)

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

·         Understand the dynamics of a particular indication in a condensed manner

·         Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more

·         Obtain discontinued trial listing for trials across the globe

·         Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies